Halozyme Therapeutics: Rapidly Rising Licensing Fees Make Halozyme a Biotech Top Pick
Reading Time: 3 minutes
The stock of Halozyme was one of the first stocks I presented in this section on July 3, 2024. Shortly before, the company received the patent for its unique Enhanze technology, which secures exclusive revenues for this key technology in 37 European countries until 2029. Since then, the stock has continued to rise sharply. Currently, it is 24% above the level on July 3 and reached a new all-time high just yesterday, on March 26. The associated high investor confidence can now serve as the foundation for further attractive price growth. Halozyme...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
